Last reviewed · How we verify
Pelvic inflammatory disease due to Mycoplasma hominis — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Zithromax | azithromycin | Pfizer Inc. | Macrolide antibiotic (azalide) | Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor | 1991-11-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer Inc. · 1 drug in Pelvic inflammatory disease due to Mycoplasma hominis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Pelvic inflammatory disease due to Mycoplasma hominis:
- Pelvic inflammatory disease due to Mycoplasma hominis treatment updates — RSS
- Pelvic inflammatory disease due to Mycoplasma hominis treatment updates — Atom
- Pelvic inflammatory disease due to Mycoplasma hominis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Pelvic inflammatory disease due to Mycoplasma hominis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pelvic-inflammatory-disease-due-to-mycoplasma-hominis. Accessed 2026-06-11.
Related
- Pelvic inflammatory disease due to Mycoplasma hominis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing